DT News - India - Israeli hospital claims new drug 'cured' 29 of 30 moderate to severe Covid patients in days

Rajeev Chitguppi, Dental Tribune South Asia

Sat. 6 February 2021

save

A medicine that was being developed for cancer has shown potential in modulating the immune response to prevent the deadly cytokine storm. Researchers call it a breakthrough as 29 of 30 phase 1 trial patients left hospital within 3-5 days.

Tel Aviv’s Ichilov Medical Center has successfully completed the phase 1 trials for a new drug that appears to have helped numerous moderate-to-serious cases to quickly recover from COVID-19. The hospital calls it a huge breakthrough as all 30 patients suffering from moderate to severe Covid-19, who received the drug recovered — 29 of them within three to five days.

EXO-CD24 -a targeted drug that was being developed as a cure for cancer for the past few years, makes use of tiny carrier sacs knows as exosomes to deliver a protein called CD24 to the lungs. The drug fights the cytokine storm, which is an overreaction to the SARS-CoV-2 infection by the immune system that is believed to be potentially lethal.

The drug EXO-CD24 is different from other molecules in that it is directly inhaled into the lungs, which happen to be the epicentres of the cytokine storm. It is to be inhaled once a day for a few minutes, for five days.

Tags:

To post a reply please login or register

New ICMR study: Rapid Antigen Test can detect COVID-19 patients within the first 5 days of illness

Rapid Antigen Test (RAT) showed an excellent specificity to 'rule-in' COVID-19 patients within the first 5 days of illness and had a moderate sensitivity. ...

Is loss of taste overestimated among COVID-19 patients?

TRIESTE, Italy: The majority of COVID-19 patients self-report olfactory and gustatory disfunction, making these among the most common symptoms of the ...

Resistance to anti-fungal drugs increased seen in severe childhood dental caries

PHILADELPHIA, U.S.: Some young children experience severe dental caries that resists normal therapies. According to a recent study carried out by ...

COVID-19 advances acceptance of teledentistry among patients

Dubai, UAE: A survey of residents in the UAE and Saudi Arabia has found that 88% of the respondents appreciate the advantages of teledentistry and online ...

New study examines extent of occupational risk of COVID-19 in UK

BIRMINGHAM, UK: To fill a research gap, researchers have recently examined whether dental professionals are, in fact, at an increased risk of becoming ...

New molecule to block COVID-19 infection

With newer variants emerging and challenging our previously acquired immunity and creating worldwide uncertainty, there is an urgent need for antiviral ...

Good oral health may prevent severe COVID-19 progression

LEIPZIG, Germany: Given that little time has passed since the outbreak of SARS-CoV-2, it comes as no surprise that only sparse data on COVID-19 is available...

Severe form of COVID 19: Mainly a vascular disease? Can 'Anaerobic Bacteria Hypothesis' explain it?

Sandeep Chakraborty (B-Tech, Electrical Engineering IIT Kharagpur, 1997), (Masters. Computer science, IIT Kharagpur, 2008) is a researcher focused on ...

US FDA grants Emergency Use Authorization (EUA) for the antiviral drug Remdesivir to treat COVID-19

The US Food and Drug Administration has granted 'Emergency Use Authorization (EUA)' for Gilead Sciences’ antiviral drug remdesivir to treat COVID-19, the ...

Education

Live webinar
Mon. 13 July 2026
9:00 pm IST (New Delhi)